Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) named one of the 20 Best Performing Stocks in 2025. Piper Sandler maintains an Overweight rating, raising price target to $100. Redemplo for FCS expected to generate significant sales in 2026 with positive Phase III data anticipated in Q3 2026. Morgan Stanley maintains Equal Weight rating with $81 price target.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a prominent American biotechnology company. While ARWR shows investment potential, other AI stocks may offer greater upside potential and lower downside risk. For a highly undervalued AI stock poised to benefit from Trump-era tariffs and onshoring trend, check out the best short-term AI stock in a free report.

For more investment opportunities, explore 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. No disclosures provided in the article.

Read more at Yahoo Finance: Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR)